

Express Mail Label No. EV139503973US
Date of Deposit: November 6, 2002

PATENT APPLICATION
Attorney Docket No.: 19904-002(Breese-2)
(formerly 19141-007)

#261
aia
11/13/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 12 2002

APPLICANTS : Piechaczyk *et al.*

SERIAL NUMBER : 09/341,894

EXAMINER : J. Woitach

FILING DATE : December 15, 1999

ART UNIT : 1632

TECH CENTER 1600/2900

FOR : BIOLOGICAL MATERIAL FOR TREATING A MAMMAL BY ANTIBODY GENE
TRANSFER AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

November 6, 2002
Boston, Massachusetts

BOX SEQUENCE LISTING

United States Patent and Trademark Office
P.O. Box 2327
Washington, D.C. 22202

**RESPONSE TO EXAMINER COMMUNICATION MAILED OCTOBER 22, 2002 AND
NOTICE TO COMPLY WITH SEQUENCE LISTING
REQUIREMENT UNDER 37 CFR §§ 1.821 - 1.825**

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 22, 2002, Applicants file this Response in order to incorporate the required SEQ ID NOs. into the specification of the U.S.S.N. 09/341,894 patent application. Applicants concurrently submit herewith a substitute computer readable form (CFR) copy of the "Sequence Listing", a substitute paper copy of the "Sequence Listing" and a statement that the content of the paper and computer readable copies are the same and include no new matter, in compliance with 37 C.F.R. §§ 1.821-1.825.

This response is due on or before November 21, 2002. Applicants believe that no fee is required for the filing of the present response. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 19904-002; Breese-2).

